We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Others Overlooked AEGON (AEG), Should You Buy It Now?
Read MoreHide Full Article
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.
So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is AEGON N.V. (AEG - Free Report) . This Insurance - Multi line stock has actually seen estimates rise over the past month for the current fiscal year by about 10.7%. But that is not yet reflected in its price, as the stock gained only 1.8% over the same time frame.
You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 17.7%, which should ultimately translate into price appreciation.
So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider AEGON. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for AEG and that now might be an interesting buying opportunity.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Image: Bigstock
Others Overlooked AEGON (AEG), Should You Buy It Now?
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.
So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is AEGON N.V. (AEG - Free Report) . This Insurance - Multi line stock has actually seen estimates rise over the past month for the current fiscal year by about 10.7%. But that is not yet reflected in its price, as the stock gained only 1.8% over the same time frame.
Aegon NV Price and Consensus
Aegon NV Price and Consensus | Aegon NV Quote
You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 17.7%, which should ultimately translate into price appreciation.
And if this isn’t enough, AEG currently carries a Zacks Rank #2 (Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider AEGON. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for AEG and that now might be an interesting buying opportunity.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>